(Date:8/8/2008)... 8 /PRNewswire-FirstCall/ -- Hanger Orthopedic,Gro... Moody,s Investors,Service revised its outlook for..."stable." Moody,s also affirmed Hanger,s corporate...ith the outlook change from Moody,s as it reflects...," remarked George McHenry,Hanger,s Chief Financi...
(Date:8/7/2008)...terone may be a key factor in spreading disease am...uld help explain why males in a population are oft...se., , Previous research has linked testosteron...ion. Studies have shown that males, compared to fe...nt for a larger share of disease transmission. How...
(Date:8/7/2008)...Engineering Initiative Marks 12th Year of Summer ...GH, Aug. 7 /PRNewswire/ -- Twenty-four undergradua...ily across southwestern Pennsylvania,and the Pitts...ummer,Internship Program of the Pittsburgh Tissue ...gram is to expose greatly increased numbers of our...
(Date:8/7/2008)... /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:,...AT study show that,once-daily EPZICOM (abacavir + ...aily Truvada(R) (tenofovir DF + emtricitabine) as ...data were presented today at the 17th,Internationa...s the first large, prospective, long-term, head-to...
Breaking Medicine News(10 mins):Health News:Testosterone key to disease transmission 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5...me of lifting, bending and normal wear and tear.//...o relieve stress while going about your daily acti...r in arthritis care. If you’ve lived long enough, ... shoulder, elbow and wrist can cause pain, swellin...
... A protein called Human beta defensin 4 (HBD4) is ... present through out the body and helps it to figh...t this could be produced by genetically modified s...f researchers led by Dorothy Supp, a researcher an...
... Prevention has reported that many have come down ...requiring// hospital admission. The number of pat...utbreak. Explaining the extent of impact, CDC sa...isted in 67 hospitals spanning 18 districts and co...
...dreaded flu or influenza is just a step away; from...03 released// the FluMist, a popular influenza vir...t which has been approved by the Food and Drug A...same name FluMist, or by its clinical name CAIV-T ...
Other Medicine News:Health News:Nine Ways to Relieve Joint Stress 2(Date:8/8/2008)...urkhalter, BOSTON, Aug. 8 /- Francis...dant fruit beverage every day could help protect,h...out after participating,in a clinical trial near h...cted by Bell Ventures, shows that after just 7 day...iovascular disease (CVD),was significantly reduce...
(Date:8/8/2008)...Innocoll, Inc., a privately-held,biopharmaceutical... dosed,in the first of three ongoing phase 2 clini...y, Innocoll Technologies Ltd, to investigate,Colla...ent of,post-operative pain., Innocoll,s BUPIVACAI...ioresorbable matrix of purified fibrillar collagen...
(Date:8/7/2008)...-- ProteoTech Inc. (ProteoTech),today announced th... Drug,(IND) requirements and has been cleared by t...l on Exebryl-1(R), a novel small molecule drug tar... the treatment of Alzheimer,s,disease. ProteoTech ...., At the 2008 International Conference on Alzhei...
(Date:8/7/2008)...ical Trial of ALXN6000 in Cancer, CHESHIRE, Conn....euticals, Inc. (Nasdaq: ALXN ) today announced th... Patent Number 7,408,041 titled,"Polypeptides and...mia,Cells and Uses Thereof." The patent is assigne...e composition-of-matter of Alexion,s anti-CD200,hu...
Breaking Medicine Technology:ViaViente Demonstrates Cardiovascular Benefits in New Human Trial 2ViaViente Demonstrates Cardiovascular Benefits in New Human Trial 3Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 2Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 3Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 4ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 2Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 3Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 4LifeNet Health and IMS Announce Partnership 1979 1LifeNet Health and IMS Announce Partnership 1979 2Clinical Data Presented on OrthoGlide 28R 29 Medial Knee Implant 932 1Clinical Data Presented on OrthoGlide 28R 29 Medial Knee Implant 932 2Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 1Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 2Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 3National Heart Lung and Blood Institute creates national network to study cardiovascular disease 7110 1National Heart Lung and Blood Institute creates national network to study cardiovascular disease 7110 2...ar 26, 2007 - Pfizer said today that,results from ...itor,stopped the progression of atherosclerosis in...hypercholesterolemia (FH). The,trials, which were ... investigational compound torcetrapib in combinati...esented today at the,annual meeting of the America...
...6, 2007 /PRNewswire/ -- DiObex,Inc., a privately-...elopment of therapeutics to treat metabolic diseas...DIO- 902, a novel Cortisol,Synthesis Inhibitor. , ...placebo-controlled trial, patients with type 2 dia...afety, pharmacokinetics and,activity of three dose...
Other Medicine Technology:Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 2Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 3Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 4Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 5Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
...nal reference laboratory and a worldwide leader in...RUP offers an extensive test menu of highly comple...c pathology. Owned by the University of Utah, ARUP...he nation's university teaching hospitals and chil...
Medicine Products: